Not Tagged
immunitybio
['pancreatic', 'immunitybio']
at #asco22, dr. tara seery presents: phase 2 clinical trial of damp inducers combined with il15 superagonist, n-803, and anti pd-l1 nk cell therapy more than doubles historical overall survival in patients with 3rd-6th line advanced pancreatic cancer. 
ImmunityBio is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system.